Abstract
Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bassi S., Albizzati M. G., Sbacchi M., Frattola L., Massarotti M. Double-blind evaluation of monosialoganglioside (GM1) therapy in stroke. J Neurosci Res. 1984;12(2-3):493–498. doi: 10.1002/jnr.490120232. [DOI] [PubMed] [Google Scholar]
- Battistin L., Cesari A., Galligioni F., Marin G., Massarotti M., Paccagnella D., Pellegrini A., Testa G., Tonin P. Effects of GM1 ganglioside in cerebrovascular diseases: a double-blind trial in 40 cases. Eur Neurol. 1985;24(5):343–351. doi: 10.1159/000115823. [DOI] [PubMed] [Google Scholar]
- Detsky A. S., Sackett D. L. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med. 1985 Apr;145(4):709–712. [PubMed] [Google Scholar]
- Orgogozo J. M., Capildeo R., Anagnostou C. N., Juge O., Péré J. J., Dartigues J. F., Steiner T. J., Yotis A., Rose F. C. Mise au point d'un score neurologique pour l'évaluation clinique des infarctus sylviens. Presse Med. 1983 Dec 29;12(48):3039–3044. [PubMed] [Google Scholar]